oasis-1 oral semaglutide 50 mg obesity nejm 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial oasis 1 oral semaglutide 50

#Pharmacovigilance #DrugSafety #PharmD #ClinicalPharmacology #LDLCholesterol #Inclisiran #BempedoicAcid #Ezetimibe #Statins #CardiometabolicHealth To view or add a comment, sign in #AgiosNews: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion for the new indication for our first-in-class pyruvate kinase (PK) activator for the treatment of anemia in adult patients with #thalassemia

Capehorn MS, Catarig AM, Furberg JK, et al

I loved that I didnt need an appointmentand I felt fantastic afterwards

This is where many people get it wrong by following trends instead of focusing on balance and proportion

Glucuronidation of Drugs and other Compounds

A new study published Wednesday in PLOS has identified neurological and neuropsychiatric symptoms headaches, vertigo, sleep problems, smell and taste disorder, depression as more likely to occur in people with what the authors term excess weight based on BMI